Medtronic settled nearly 1,000 Infuse bone graft lawsuits for $22 million and set aside at least $120 million to settle thousands of additional claims. If you were injured, there may still be time to join this litigation.
What is the Infuse Bone Graft?
Medtronic Inc. manufactures the INFUSE Bone Graft, a product used in spinal-fusion surgery. Traditionally, spinal fusion requires harvesting bone from another area of the patient’s body to be transplanted in the surgical area. Infuse is designed with a bone-growth protein, human bone morphogenetic protein (rhBMP). It has been used in over 1 million patients since it was approved in 2002.
Infuse Bone Graft Class Action Lawsuit Information
Medtronic Inc. is facing over 3,000 lawsuits involving complications of the INFUSE Bone Graft. In May 2014, 950 lawsuits were settled for $22 million and $120-140 million was set aside to settle the rest. These lawsuits are not consolidated as part of an Infuse bone graft class action. Instead, they are individual lawsuits filed by people who have hired their own lawyer.
Plaintiffs in this litigation allege that Medtronic paid hundreds of millions of dollars in royalties and consulting fees to doctors who produced research that was favorable to Infuse, but downplayed risks.
At the peak of its popularity, over 85% of Infuse sales were for “off-label” purposes that were never approved by the FDA. In 2008, the FDA warned about life-threatening swelling and other complications that could occur when Infuse was used in the neck.